Overview
BMS-741672 for Diabetic Neuropathic Pain
Status:
Completed
Completed
Trial end date:
2009-02-01
2009-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of the study is to determine whether BMS-741672 improves neuropathic pain in diabetic patients.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Bristol-Myers Squibb
Criteria
Inclusion Criteria:- Type 1 or 2 diabetics with painful, distal, symmetrical, sensory-motor neuropathy
attributed to diabetes, of at least 12 months duration
- Screening HbA1c of ≥ 7% and ≤ 10%
- BMI ≤ 40 kg/m2
Exclusion Criteria:
- Patients with clinically significant, progressive, or potentially unstable disease of
any body system including cardiovascular, gastrointestinal, central nervous system
(CNS), psychiatric, endocrine (other than diabetes), tuberculosis or renal
- Women of childbearing potential